Attestato di partecipazione
Introduzione
This course addresses safety aspects related to clinical trials, in particular those pharmacovigilance activities and requirements related to the preparation of the Development Safety Update Report (DSUR) according to the ICH E2F guidance. Structure and content of DSURs will be described. Furthermore, recent requirements based on the EU-CTR will be presented.
Among the ongoing pharmacovigilance activities that support the preparation of DSURs, the process of signal detection and signal management will be in the focus of this course, with a special focus on post-marketing activities.
Pharmacovigilance Documents – Focus on Signal Management and Development Safety Update Reports (DSUR)
“The early phases: Signals and Trials”
- Focus on the Development Safety Update Report (DSUR)
- Who, when, what and how.
- Breakout sessions and interactive discussion of the results
- Signal management
- Evaluation of sources
- Signal management and data collection
- The Signal Detection and Management Report
- Breakout sessions and interactive discussion of the results
- Assessment and review of key concepts
Professionals involved in the planning, preparation, coordination and review of aggregated safety reports.
In particular:
Drug Safety and Pharmacovigilance department, Regulatory Affairs department and Quality and Compliance department (e.g. medical writers, pharmacovigilance writers, pharmacovigilance officers, pharmacovigilance managers, QPPVs, safety physicians, managers regulatory affairs and medical evaluators/advisors, document quality and compliance managers).
Participant experience
For the participation in these training courses is required:
- Previous attendance to the “Pharmacovigilance Documents – Basic Concepts and Definitions for Pharmacovigilance Writing” training
- In alternative, a basic knowledge of PV writing
Presentation, hands-on exercises, group, and class discussions with a limited number of attendees.
Docente/i
Marco Anelli
Marco has a medical degree from the University of Milan, specializations in Medical Statistics and Clinical Pharmacology from the University of Pavia and an international master’s degree in health economics and pharmacoeconomics from the University of Pompeu Fabra in Barcelona, plus formal training in Data Science and Artificial Intelligence.
In the last few years, he has extensively worked in the fields of pharmacoeconomics and health technology assessment.
Marco has been a free-lance consultant in Medical Affairs and Pharmacovigilance/ Drug Safety since 2022.
Before that, he has been “Head of Pharmacovigilance and Medical Affairs Advisory Services” at ProductLife Group (PLG).
As “Deputy Chief Scientific Officer”, always at PLG, Marco has also coordinated all delivery and research projects (internal and on behalf of clients) linked to Big Data, Knowledge Management, Artificial Intelligence and Machine Learning.
Previously, Marco was R&D Director at Keypharma, an Italy-based consultancy company (later acquired by PLG), where was responsible for the oversight of all clinical and preclinical aspects of projects run internally and on behalf of clients.
Drawing on a career in the pharmaceutical industry that spans more than 30 years, Marco provides expert oversight on a wide range of R&D and Medical Affairs related activities.
Marco has participated in and supervised all stages of drug development – from formulation to Phase I-IV and pharmacovigilance.
In addition, Marco is a qualified QPPV and has prepared and overseen more than 200 non-clinical and clinical overviews and summaries.
Before joining Keypharma and PLG, Marco was Medical Affairs Director at Eurand.
Tiziana von Bruchhausen
Tiziana von Bruchhausen, PhD specialises in pharmacovigilance writing and has gained over 10 years’ experience while working in various roles for mid-sized and large pharmaceutical companies. She is currently employed as a principal pharmacovigilance writer at Boehringer Ingelheim. Her tasks and responsibilities cover pre- and post-submission activities related to the global strategic planning and the preparation of pharmacovigilance documents with a focus on DSURs, RMPs, PSURs, and health authorities’ assessment reports.
Tiziana actively promotes the professional role of medical writers in pharmacovigilance through workshops and lectures Europe-wide and has served as a session chair at international conferences. She is an active volunteer at the European Medical Writers Association (EMWA), where she has been chairing since 2017 the Pharmacovigilance Special Interest Group Committee. She was Vice President of EMWA in 2017-2018 and President in 2018-2019.
Online Training – 1 module
25 September 2024 from 01:30 pm to 05:30 pm CEST
The training course admits maximum 12 attendees.
The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.
***
This course is part of the training path “Pharmacovigilance Documents in the Life Cycle of a Medicinal Product”.
Early Bird: € 510,00* (until 04 September 2024)
Ordinary: € 645,00 *
Freelance – Individual – Academy – Public Administration**: € 435,00 *
* for Italian companies: +22% VAT
** Early Bird discount not applicable to Freelance – Individual – Academy – Public Administration fee
The fee includes: tuition, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.
Registrati
Roberta Alberti
Events & Training Manager
Cosa saprai fare dopo il corso
Online interactive training on Zoom platform.
LS Academy will provide the access link to the virtual platform a few days before the training.
